{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-014028","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.245925+00:00","generated_at":"2026-06-06T04:22:25.901216+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioXcel Therapeutics amends credit to waive going concern; FDA Fast Track for BXCL701","bullets":["Lenders waived 2023 going concern covenant; requires at least $40M equity raise by Feb 20, 2024.","FDA granted Fast Track designation for BXCL701 + checkpoint inhibitor in metastatic small cell neuroendocrine prostate cancer.","Third Amendment to Oaktree credit agreement avoids default but with capital raise condition.","Condition subsequent: Borrower must receive $40M gross proceeds from public sale of stock/warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-014028","json":"https://secwatch.observer/filing/0001104659-24-014028.json","markdown":"https://secwatch.observer/filing/0001104659-24-014028.md","text":"https://secwatch.observer/filing/0001104659-24-014028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924014028/0001104659-24-014028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924014028/tm244487d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:22:25.901216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0719b7dd473800bcf9993472910d25612e474fbb","claim":"BioXcel Therapeutics, Inc. amended Third Amendment to Credit Agreement and Guaranty with Oaktree Fund Administration LLC, as administrative agent, and the lenders (effective 2024-02-12).","evidence_excerpt":"On February 12, 2024, BioXcel Therapeutics, Inc. (the “Company”) entered into the Third Amendment to Credit Agreement and Guaranty (the “Third Amendment”), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the “Lenders”), and Oaktree Fund Administration LLC (“OFA”) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, and the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the “Existing Credit Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924014028/0001104659-24-014028-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oaktree Fund Administration LLC, as administrative agent, and the lenders"},{"label":"Effective","value":"2024-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}